<DOC>
	<DOC>NCT00191971</DOC>
	<brief_summary>To investigate efficacy and safety of 2nd line GEM monotherapy after CDDP regimen for patients with transitional cell carcinoma of urothelium</brief_summary>
	<brief_title>2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Transitional Cell</mesh_term>
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically and/or cytologically confirmed TCC Received 1st line chemotherapy for locally advanced or metastatic TCC with CDDP regimen To have at least one measurable region PS: 02 To have adequate organ function (bone marrow, liver and renal function) To have Interstitial pneumonia or pulmonary fibrosis Within 4 weeks after the latest chemotherapy or radiotherapy To have brain metastasis with symptom To have severe complication (cardiac infarction, infection, drug hyper sensitivity or diabetes)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Transitional cell carcinoma of urothelium</keyword>
</DOC>